BACKGROUND: The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort. METHODS: Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years. RESULTS:A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6). CONCLUSIONS: The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.
RCT Entities:
BACKGROUND: The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort. METHODS: Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years. RESULTS: A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6). CONCLUSIONS: The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.
Authors: Steven R Schwid; Janice Bausch; David Oakes; Lynn Schuchter; Caroline Tanner; Misser Forrest; Anthony E Lang; Ira Shoulson; Ira Shoulson; Christopher Hyson; David Oakes; Emily Flagg; Alice Rudolph; Karl Kieburtz; Anthony Lang; Stanley Fahn; Lisa Gauger; Christopher Goetz Journal: Mov Disord Date: 2010-09-15 Impact factor: 10.338
Authors: Lauren A Dalvin; Gena M Damento; Barbara P Yawn; Barbara A Abbott; David O Hodge; Jose S Pulido Journal: Mayo Clin Proc Date: 2017-07 Impact factor: 7.616
Authors: Pawel Tacik; Sadie Curry; Shinsuke Fujioka; Audrey Strongosky; Ryan J Uitti; Jay A van Gerpen; Nancy N Diehl; Michael G Heckman; Zbigniew K Wszolek Journal: Parkinsonism Relat Disord Date: 2016-06-20 Impact factor: 4.891
Authors: Svetlana Bivol; George D Mellick; Jacob Gratten; Richard Parker; Aoibhe Mulcahy; Philip E Mosley; Peter C Poortvliet; Adrian I Campos; Brittany L Mitchell; Luis M Garcia-Marin; Simone Cross; Mary Ferguson; Penelope A Lind; Danuta Z Loesch; Peter M Visscher; Sarah E Medland; Clemens R Scherzer; Nicholas G Martin; Miguel E Rentería Journal: BMJ Open Date: 2022-02-25 Impact factor: 3.006